By Dr Maya Kansara

Conference Abstracts

Southi N; Sim H-W; Grady J; Satgunaseelan L; Huang M; Kansara M; Yuile A; Zaman A; Lin F; Wheeler H; Hudson A; Ballinger ML; Thomas DM; Thavaneswaran S, 2025, 'PATH-52. Understanding the prevalence ofMTAP andCDKN2A/B deletion in gliomas by next generation sequencing', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v252 - v252, http://dx.doi.org/10.1093/neuonc/noaf201.1004

Thavaneswaran S; Espinoza D; Lin FP; Chinchen S; Kansara M; Ballinger M; Grady J; Grimison P; Millward M; Ladwa R; Joshua AM; Desai J; Simes J; Thomas D, 2025, '973P Phase II trial of Vismodegib in advanced cancers with Hedgehog pathway alterations', in Annals of Oncology, Elsevier, Vol. 36, pp. s637, http://dx.doi.org/10.1016/j.annonc.2025.08.1542

Lin FPY; Grady JP; Napier CE; Callow M; Thavaneswaran S; Huang ML; Zaheed M; Kansara M; Sebastian L; Ballinger ML; Simes J; Thomas DM, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.', in Journal of Clinical Oncology, Vol. 42, pp. 1557 - 1557, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.1557

Lin FP-Y; Grady JP; Napier CE; Callow M; Thavaneswaran S; Huang ML; Zaheed M; Kansara M; Sebastian L; Ballinger ML; Simes J; Thomas DM, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board', in Journal of Clinical Oncology, American Society of Clinical Oncology, Vol. 42, presented at 2024 ASCO Annual Meeting I, 29 May 2024 - 29 May 2024, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.1557

Napier CE; Lin F; Thavaneswaran S; Sebastian L; Grady J; Kansara M; Zaheed M; Simes J; Ballinger ML; Thomas DM, 2024, 'Pattern of access to genomically-linked therapies associated with pan-cancer biomarkers in advanced cancer patients: Insights from the Australian Molecular Screening and Therapeutics (MoST) program', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 136 - 136

Kansara M; Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Kansara M; Sebastian L; Kee D; Zaheed M; Millward M; Brown MP; Charakidis M; Craft PS; Grimison PS; Harrup RA; O'Byrne KJ; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Thavaneswaran S; Mersiades A; Lin FP-Y; Espinoza D; Grady JP; Lee CK; Desai J; Brown MP; Grimison PS; O'Byrne KJ; Harrup RA; Nagrial A; Sebastian L; Chinchen S; Kansara M; Craft PS; Simes MMJ; Joshua AM; Thomas DM, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Huang M; Kansara M; Qiu M; Thomas D, 2023, 'NTRK transcript expression and Pan-TRK protein expression in advanced rare solid tumours', in HISTOPATHOLOGY, WILEY, Vol. 83, pp. 34 - 34

, 2023, 'Special Session – Molecular Pathology', in Histopathology, Wiley, Vol. 83, pp. 34 - 34, http://dx.doi.org/10.1111/his.14990

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3073

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11546 - 11546, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11546

Thomas DM, 2022, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', in CANCER SCIENCE, WILEY, Vol. 113, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778583800159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thavaneswaran S; Sebastian L; Finlayson S; Desai J; O'Byrne K; Harrup R; Ballinger ML; Lin F; Grady JP; Kansara M; Simes J; Leland SM; Jansen VM; Cavers AC; Thomas DM, 2021, 'CRESTONE: Clinical Study of REsponse to Seribantumab in Tumours with NEuregulin-1 (NRG1) Fusions: A phase 2 study of the anti-HER3 monoclonal antibody for advanced or metastatic solid tumours (MoST CRESTONE in Australia)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 206 - 206, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500346&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Scientific Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 02 June 2020

Thavaneswaran S; Ballinger ML; Grady J; Cowley M; Joshua A; Sebastian L; Collignon E; Silvestri A; Kansara M; Pinese M; Sjoquist KM; Hague W; Lee CK; Simes J; Thomas DM, 2019, 'The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 3136 - 3136, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3136

Back to profile page